Statin Therapy and COVID-19 Infection
STACOV
1 other identifier
observational
2,159
1 country
1
Brief Summary
Considering that simvastatin, and probably statins in general, interfere with SARS-cov-2 cellular uptake and some inflammatory pathways activated by the virus, those patients on statin therapy should be less vulnerable to infection and their clinical course and prognosis should be better than that in individuals not on statin therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2020
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 14, 2020
CompletedFirst Submitted
Initial submission to the registry
May 27, 2020
CompletedFirst Posted
Study publicly available on registry
May 29, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 20, 2020
CompletedStudy Completion
Last participant's last visit for all outcomes
December 30, 2020
CompletedMarch 11, 2021
March 1, 2021
3 months
May 27, 2020
March 9, 2021
Conditions
Outcome Measures
Primary Outcomes (1)
SARS-cov-2 scale of severity (9 steps) in Covid-19 infected patients with statin therapy
Assess the difference in the WHO SARS-cov-2 scale of severity (9 steps) achieved by Covid-19 infected patients, admitted in the hospital, with and without background statin therapy comparable in age and gender distribution
at the time of admission
Study Arms (2)
with statins
Covid-19 infected patients with statins
without statins
Covid-19 infected patients without statins
Interventions
Eligibility Criteria
This is a retrospective observational multicentre study based on clinical records review. The following centres will take part in the study: LIPIDCAS Group: * Hospital Universitari Sant Joan * Hospital Universitari Joan XXIII * Hospital Sant Pau i Santa Tecla * Hospital Verge de la Cinta * Pius Hospital de Valls * Hospital del Vendrell Other centres from the LIPID AND ARTERIOSCLEROSIS UNITS NET (XULA) from Catalonia.
You may qualify if:
- Patients ≥ 18 years old with a PCR or immunological confirmation of Covid-19 infection, admitted in the hospital for at least 24 hours, will be included.
You may not qualify if:
- Patients \< 18 years old.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Facultat de Medicina i Ciències de la Salut de Reus
Reus, Tarragona, 43201, Spain
Related Publications (1)
Masana L, Correig E, Rodriguez-Borjabad C, Anoro E, Arroyo JA, Jerico C, Pedragosa A, Miret M, Naf S, Pardo A, Perea V, Perez-Bernalte R, Plana N, Ramirez-Montesinos R, Royuela M, Soler C, Urquizu-Padilla M, Zamora A, Pedro-Botet J. Effect of statin therapy on SARS-CoV-2 infection-related mortality in hospitalized patients. Eur Heart J Cardiovasc Pharmacother. 2022 Feb 16;8(2):157-164. doi: 10.1093/ehjcvp/pvaa128.
PMID: 33135047RESULT
MeSH Terms
Conditions
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Lluís Masana, Dr
Institut Investigacio Sanitaria Pere Virgili
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr
Study Record Dates
First Submitted
May 27, 2020
First Posted
May 29, 2020
Study Start
May 14, 2020
Primary Completion
August 20, 2020
Study Completion
December 30, 2020
Last Updated
March 11, 2021
Record last verified: 2021-03
Data Sharing
- IPD Sharing
- Will not share